ClinicalTrials.govpublic full text
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
respiratory syncytial virus infections, respiratory syncytial virus, immunogenicity, safety, increased risk of respiratory syncytial virus lower respiratory tract disease, adults aged 50-59 years of age, older adults 60 years of age and above, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 872787
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.